Showing results (331-340 of 367) with videos related to
Sort By:
Pageof 37
The New England Journal of Medicine|March 23, 2022
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast CancerJavier Cortés, Sung-Bae Kim, Wei-Pang Chung, et al.The Lancet. Oncology|August 11, 2020
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket studySusan M Domchek, Sophie Postel-Vinay, Seock-Ah Im, et al.Nature Medicine|June 1, 2024
Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trialToru Mukohara, Yeon Hee Park, David Sommerhalder, et al.Oncotarget|November 4, 2015
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancerJi Yun Lee, Kyunghee Park, Sung Hee Lim, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2025
Proliferation of tumor-related regulatory T cells in circulation dictates efficacy of chemoimmunotherapy in triple-negative breast cancerSeung Hyuck Jeon, Koung Jin Suh, Sungmin Jung, et al.The Lancet. Oncology|November 1, 2019
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trialYeon Hee Park, Tae-Yong Kim, Gun Min Kim, et al.The New England Journal of Medicine|June 2, 2025
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast CancerFrançois-Clément Bidard, Erica L Mayer, Yeon Hee Park, et al.Nature Communications|May 2, 2018
Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signaturesZhengyan Kan, Ying Ding, Jinho Kim, et al.Journal of Breast Cancer|January 30, 2026
Prospective Single-Arm Study of Endocrine Therapies With Ovarian Function Suppression in Premenopausal Node-Positive Early Breast Cancer Patients With Low Genomic Risk (INTERSTELLAR Trial, KBCSG-25)Sung Gwe Ahn, Sung Hoon Sim, Taewoo Kang, et al.Breast Cancer Research and Treatment|June 3, 2015
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)Yeon Hee Park, Kyung Hae Jung, Seock-Ah Im, et al.Pageof 37